BEEuropean pharmaceutical companies are warning that increased U.S.-based 'most-favored-nation' deals under the Trump administration could lead to reduced investment in Europe. These deals require drugmakers to sell new medications in the U.S. at prices comparable to those in Europe, while committing them to invest in American facilities. The U.S. has now signed 26 such agreements, including nine newly announced ones, with at least $19.6 billion pledged in investments. This strategy aims to lower drug costs for Americans but risks reducing innovation and investment in Europe, as companies may avoid launching new drugs there to preserve higher profit margins in the U.S. European industry representatives express concern over this trend, noting that efforts like patent extensions for biotech drugs are seen as insufficient or delayed compared to the advantages offered by the U.S. market.
Bias read (Center): The article presents both the U.S. government's actions and the concerns raised by European pharmaceutical stakeholders without overtly favoring either side. It includes direct quotes from industry representatives and outlines the potential economic implications for Europe without editorializing or
